BioSpace News Archive

November in-store fundraising campaign to support Alzheimer’s Association’s efforts to help those at greater risk of COVID-19

Three-day virtual conference features over 100 internationally renowned faculty discussing latest clinical insights and data for the future of cancer care.

Dialysis Patient Citizens introduced Dialysis Plan Choice, a new online tool designed in collaboration with Consumers’ Checkbook for dialysis patients to quickly and easily compare their current Medicare Fee-For-Service plan with the options available to them through Medicare Advantage now that Open Enrollment is underway.

Alex Trebek’s Brave Battle and The Recent Passing of Supreme Court Justice Ruth Bader Ginsburg and Rep. John Lewis, Lead to Increased Public Awareness of Pancreatic Cancer

Paratek Pharmaceuticals, Inc. announced that on October 30, 2020, the Company granted stock options and restricted stock units to two new employees of the Company.

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has begun dosing patients in the Phase 2 expansion cohorts of the Phase 1/2 clinical studies for GRANITE and SLATE, its neoantigen-based immunotherapies.

Immunomic Therapeutics, Inc. will present preclinical data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses when used with its investigational UNITE vaccine, ITI-3000, in mice.

PolarityTE, Inc. (Nasdaq: PTE) announced that it recently received written responses from FDA following a Type B Pre-IND meeting request that the Company submitted in August 2020 regarding an indication for SkinTE to treat diabetic foot ulcers (DFUs)

BLA and MAA on-track for Q4 submission for regulatory approval of Sci-B-Vac ® in the U.S. and Europe Secured contributions from the Canadian Government (up to CAD$56 million) and the National Research Council of Canada (up to CAD$1 million) for development and scale-up manufacturing of coronavirus program Initial adaptive Phase 1/2 clinical study of coronavirus vaccine program expected to begin around year-end 2020

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s third quarter 2020 financial results will be released after market close on Monday, November 9, 2020